Entera Bio Ltd. (ENTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Entera Bio Ltd., an emerging growth company incorporated in Israel, on November 23, 2022, regarding an event dated November 21, 2022. The Company's ordinary shares and warrants trade on the Nasdaq Capital Market under the symbols ENTX and ENTXW, respectively.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report addresses a regulatory listing status rather than financial performance results.
Material Changes
On November 21, 2022, the Company received a notice from Nasdaq stating that its ordinary shares failed to comply with the $1.00 minimum bid price requirement for continued listing (Nasdaq Listing Rule 5550(a)(2)). This non-compliance was based on the closing bid price for the 30 consecutive business days prior to the notice date.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-day compliance period, ending May 22, 2023, to regain compliance.
- Regaining Compliance: Compliance will be achieved if the closing bid price reaches at least $1.00 for 10 consecutive business days before the deadline.
- Secondary Compliance Option: If the initial period is unsuccessful, the Company may qualify for an additional 180-day period. This requires meeting all other initial listing standards (excluding bid price) and may necessitate a reverse stock split.
- Delisting Risk: Failure to qualify for or succeed in the second compliance period could result in delisting, subject to an appeal process.
- Operational Impact: Management states that receipt of the notice has no effect on the Company's business operations.
Investor Verification Checklist
- Monitor the daily closing bid price of ENTX to track progress toward the $1.00 threshold.
- Verify if the Company announces a reverse stock split if the initial compliance period expires without success.
- Review subsequent filings for updates on the Company's status regarding the May 22, 2023, deadline.
- Confirm the Company's market value of publicly held shares to assess eligibility for the second compliance period.